Japan's Otsuka Pharma has agreed to take control of US biotech Jnana Therapeutics in a deal that will give it rights to a clinical-stage candidate for the rare metabolic disorder phenylketonuria ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果